|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.1 USD | +0.27% |
|
-5.63% | -12.87% |
| 03:11pm | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
| 13/05 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
UroGen Pharma Ltd. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 23.53 million compared to USD 18.09 million a year ago. Net loss was USD 26.02 million compared to USD 28.87 million a year ago.
Basic loss per share from continuing operations was USD 0.72 compared to USD 1.25 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -12.87% | 45Cr | |
| +5.66% | 11TCr | |
| +11.23% | 11TCr | |
| -12.15% | 2.23TCr | |
| -3.76% | 2.19TCr | |
| -6.17% | 1.86TCr | |
| -36.52% | 1.81TCr | |
| -10.09% | 1.7TCr | |
| +4.09% | 1.37TCr | |
| +36.58% | 1.24TCr |
UROGEN PHARMA LTD. 